| Literature DB >> 29550075 |
Ibtehaj Naqvi1, Ruwan Gunaratne1, Jessica E McDade2, Angelo Moreno2, Rachel E Rempel2, Douglas C Rouse3, Silvia Gabriela Herrera4, David S Pisetsky5, Jaewoo Lee2, Rebekah R White6, Bruce A Sullenger7.
Abstract
Nucleic acid binding polymers (NABPs) have been extensively used as vehicles for DNA and RNA delivery. More recently, we discovered that a subset of these NABPs can also serve as anti-inflammatory agents by capturing pro-inflammatory extracellular nucleic acids and associated protein complexes that promote activation of toll-like receptors (TLRs) in diseases such as lupus erythematosus. Nucleic-acid-mediated TLR signaling also facilitates tumor progression and metastasis in several cancers, including pancreatic cancer (PC). In addition, extracellular DNA and RNA circulate on or within lipid microvesicles, such as microparticles or exosomes, which also promote metastasis by inducing pro-tumorigenic signaling in cancer cells and pre-conditioning secondary sites for metastatic establishment. Here, we explore the use of an NABP, the 3rd generation polyamidoamine dendrimer (PAMAM-G3), as an anti-metastatic agent. We show that PAMAM-G3 not only inhibits nucleic-acid-mediated activation of TLRs and invasion of PC tumor cells in vitro, but can also directly bind extracellular microvesicles to neutralize their pro-invasive effects as well. Moreover, we demonstrate that PAMAM-G3 dramatically reduces liver metastases in a syngeneic murine model of PC. Our findings identify a promising therapeutic application of NABPs for combating metastatic disease in PC and potentially other malignancies.Entities:
Keywords: damage-associated molecular patterns; metastasis; nucleic acid binding polymer
Mesh:
Substances:
Year: 2018 PMID: 29550075 PMCID: PMC6079560 DOI: 10.1016/j.ymthe.2018.02.018
Source DB: PubMed Journal: Mol Ther ISSN: 1525-0016 Impact factor: 12.910